News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
35,059 Results
Type
Article (1094)
Company Profile (5)
Press Release (33962)
Multimedia
Podcasts (1)
Webinars (1)
Section
Business (14938)
Career Advice (37)
Deals (2043)
Drug Delivery (6)
Drug Development (4247)
Employer Resources (8)
FDA (663)
Job Trends (917)
News (19929)
Policy (1061)
Tag
Academia (70)
Accelerated approval (3)
ADA (1)
Adcomms (1)
Allergies (11)
Alliances (957)
ALS (8)
Alzheimer's disease (131)
Antibody-drug conjugate (ADC) (45)
Approvals (776)
Artificial intelligence (33)
ASCO (26)
Autoimmune disease (25)
Automation (1)
Bankruptcy (3)
Best Places to Work (904)
BIO (3)
Biologics (1)
BIOSECURE Act (1)
Biosimilars (8)
BioSpace Insights (2)
Biotechnology (5)
Bladder cancer (39)
Brain cancer (3)
Breast cancer (80)
Cancer (635)
Cardiovascular disease (36)
Career advice (38)
Career pathing (2)
CAR-T (18)
CDC (2)
CDMO (2)
Celiac Disease (1)
Cell therapy (51)
Cervical cancer (6)
Clinical research (4439)
Collaboration (95)
Commercialization (2)
Compensation (71)
Complete response letters (4)
COVID-19 (116)
CRISPR (8)
C-suite (26)
Cystic fibrosis (9)
Data (968)
Depression (6)
Dermatology (13)
Diabetes (42)
Diagnostics (425)
Digital health (4)
Diversity, equity & inclusion (2)
Drug discovery (13)
Drug pricing (5)
Duchenne muscular dystrophy (53)
Earnings (14653)
Editorial (1)
Employer branding (1)
Employer resources (7)
Events (3155)
Executive appointments (27)
FDA (1132)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (73)
Gene editing (16)
Generative AI (5)
Gene therapy (42)
GLP-1 (82)
Government (123)
Guidances (179)
Healthcare (953)
Hematology (12)
HIV (6)
Huntington's disease (3)
IgA nephropathy (10)
Immunology and inflammation (30)
Immuno-oncology (5)
Indications (30)
Infectious disease (149)
Inflammatory bowel disease (19)
Influenza (11)
Intellectual property (11)
Interviews (2)
IPO (1612)
Job creations (84)
Job search strategy (34)
JPM (1)
Kidney cancer (4)
Labor market (4)
Layoffs (18)
Leadership (3)
Legal (126)
Longevity (2)
Lung cancer (112)
Lymphoma (62)
Machine learning (2)
Management (4)
Manufacturing (50)
Marketing (2)
MASH (25)
Medical device (884)
Medtech (896)
Mergers & acquisitions (517)
Metabolic disorders (126)
mRNA (13)
Multiple sclerosis (20)
NASH (2)
Neurodegenerative disease (23)
Neuropsychiatric disorders (8)
Neuroscience (231)
NextGen: Class of 2026 (185)
Non-profit (114)
Now hiring (1)
Obesity (52)
Opinion (6)
Ovarian cancer (21)
Pain (17)
Pancreatic cancer (23)
Parkinson's disease (24)
Partnered (1)
Patents (25)
Patient recruitment (34)
Peanut (2)
People (837)
Peptides (1)
Pharmaceutical (1)
Pharmacy benefit managers (1)
Phase 1 (988)
Phase 2 (1840)
Phase 3 (1948)
Pipeline (1673)
Policy (6)
Postmarket research (151)
Preclinical (229)
Prostate cancer (42)
Psychedelics (5)
Radiopharmaceuticals (20)
Rare diseases (93)
Real estate (77)
Recruiting (2)
Regulatory (1204)
Reports (4)
Research institute (43)
Rett syndrome (7)
RNA editing (1)
RSV (9)
Schizophrenia (16)
Series A (8)
Series B (4)
Sickle cell disease (9)
Special edition (1)
Spinal muscular atrophy (16)
Sponsored (2)
Startups (45)
Stomach cancer (1)
Supply chain (2)
Tariffs (2)
The Weekly (1)
Vaccines (61)
Venture capital (1)
Weight loss (31)
Women's health (7)
Worklife (2)
Date
Today (4)
Last 7 days (34)
Last 30 days (126)
Last 365 days (2562)
2026 (1766)
2025 (2653)
2024 (2693)
2023 (2771)
2022 (4328)
2021 (3094)
2020 (2576)
2019 (2016)
2018 (1585)
2017 (1584)
2016 (1046)
2015 (1415)
2014 (889)
2013 (674)
2012 (723)
2011 (833)
2010 (794)
Location
Africa (28)
Alabama (1)
Arizona (16)
Asia (2116)
Australia (275)
California (1194)
Canada (293)
China (141)
Colorado (88)
Connecticut (53)
Delaware (61)
Europe (6225)
Florida (227)
Georgia (34)
Hawaii (1)
Idaho (1)
Illinois (97)
India (6)
Indiana (66)
Japan (65)
Kansas (8)
Kentucky (8)
Louisiana (7)
Maine (5)
Maryland (158)
Massachusetts (759)
Michigan (59)
Minnesota (56)
Missouri (9)
Montana (2)
Nevada (16)
New Hampshire (6)
New Jersey (456)
New York (389)
North Carolina (148)
Northern California (671)
Ohio (37)
Oregon (3)
Pennsylvania (227)
Rhode Island (1)
South America (49)
South Carolina (3)
Southern California (447)
Tennessee (12)
Texas (162)
United States (4504)
Utah (41)
Virginia (15)
Washington D.C. (2)
Washington State (195)
Wisconsin (12)
35,059 Results for "71".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
February 5, 2026
·
10 min read
Approvals
BMS welcomes new multiple myeloma drug as generics batter current portfolio
The FDA approves Zenbexus just as copycat competitors depress sales of Bristol Myers Squibb’s multiple myeloma drugs Pomalyst and Revlimid, which crashed 71% and 49% year-on-year, respectively, in the second quarter.
August 14, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 16, 2026
·
6 min read
Press Releases
Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 17, 2026
·
6 min read
Press Releases
High Potency Active Pharmaceutical Ingredients Market Poised for Growth, Expected to Hit USD 71.39 Billion by 2032-Coherent Market Insights
November 3, 2025
·
1 min read
Press Releases
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
• 71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002) • The two remaining patients who have not yet reached the 3-year timepoint from enrollment have trial monitoring visits scheduled for September 2026 and early October 2026 • Company receives $3.15 million in VAT refunds into OS Therapies UK, Ltd. subsidiary, with an additional $7.2 million in refundable VAT and R&D Tax Credits pending
September 8, 2026
·
8 min read
Psychedelics
Cybin’s Small Depression Study Shows 71% Remission Rate
Phase II results for Cybin’s psilocin therapy showed remission rates of 71%, but just eight patients made it to the 12-month milestone.
November 18, 2024
·
2 min read
·
Annalee Armstrong
Press Releases
Non-Small Cell Lung Cancer Therapeutics Market Eyes $71.2 Billion Milestone by 2034
June 17, 2025
·
1 min read
Press Releases
Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval
March 4, 2026
·
4 min read
Press Releases
Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
December 11, 2025
·
11 min read
1 of 3,506
Next
